Peapack Gladstone Financial Corp Sells 8,244 Shares of Edwards Lifesciences Corporation $EW

Peapack Gladstone Financial Corp lowered its position in Edwards Lifesciences Corporation (NYSE:EW) by 3.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 261,416 shares of the medical research company’s stock after selling 8,244 shares during the period. Peapack Gladstone Financial Corp’s holdings in Edwards Lifesciences were worth $22,286,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in EW. JPL Wealth Management LLC bought a new stake in Edwards Lifesciences in the third quarter worth about $25,000. Kohmann Bosshard Financial Services LLC bought a new stake in Edwards Lifesciences in the fourth quarter worth about $28,000. Hantz Financial Services Inc. lifted its stake in Edwards Lifesciences by 76.6% in the third quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock worth $29,000 after purchasing an additional 164 shares during the last quarter. Dorato Capital Management bought a new stake in Edwards Lifesciences in the fourth quarter worth about $29,000. Finally, Rakuten Securities Inc. increased its position in shares of Edwards Lifesciences by 413.7% during the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after acquiring an additional 302 shares during the period. Institutional investors own 79.46% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. The Goldman Sachs Group reaffirmed a “buy” rating and set a $95.00 target price (down from $108.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Mizuho set a $95.00 target price on shares of Edwards Lifesciences and gave the stock an “outperform” rating in a research report on Monday, April 13th. Canaccord Genuity Group set a $85.00 target price on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research report on Friday, April 24th. Truist Financial set a $90.00 target price on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research report on Friday, April 24th. Finally, Evercore reaffirmed an “outperform” rating and set a $93.00 target price on shares of Edwards Lifesciences in a research report on Friday, April 24th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $95.65.

Insider Activity at Edwards Lifesciences

In other news, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the sale, the senior vice president directly owned 15,334 shares in the company, valued at approximately $1,319,950.72. The trade was a 3.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 620 shares of the business’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $81.14, for a total transaction of $50,306.80. Following the transaction, the vice president owned 40,411 shares of the company’s stock, valued at $3,278,948.54. This represents a 1.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 95,057 shares of company stock valued at $7,874,217. 0.31% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $86.41 on Monday. The firm has a market cap of $49.76 billion, a price-to-earnings ratio of 45.96, a PEG ratio of 2.17 and a beta of 0.87. The company’s 50 day moving average is $81.73 and its 200 day moving average is $83.00. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $88.28.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. During the same period in the previous year, the company earned $0.64 earnings per share. The business’s revenue for the quarter was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, sell-side analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.